Bli medlem
Bli medlem

Du är här


Dako Denmark A/S: Dako, an Agilent Technologies Company, announces expanded collaboration with Amgen within companion diagnostics

GLOSTRUP, Denmark, March 24, 2015. Dako, an Agilent Technologies company
worldwide provider of cancer diagnostics
, today announced a new Master Collaboration Agreement with Amgen Inc., a
leading biotechnology company.

The expanded collaboration will allow both companies to benefit from
knowledge-sharing within the field of drug-diagnostic research and
development in general, and in relation to companion diagnostic products in
particular. This collaboration is important in the area of personalized
medicine, where targeted treatments and companion diagnostics can help
identify patients for whom a particular treatment may work, leading to
improved patient care and more manageable healthcare costs.

"We are proud to both continue and broaden our multi-year partnership with
Amgen," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics
Group. "Together we will continue our work in the development of high-quality
companion diagnostic products to enable physicians and pathologists to
identify cancer patients who are more likely to respond to a specific

Today's announcement follows several other collaborative agreements in the
companion diagnostics area. Agilent's Dako business has partnerships with
several top-tier pharma companies for the development of companion
diagnostics. Its track record and experience in companion diagnostic
development continues to attract new partners, as well as add new projects
with current partners.

The financial details of the agreement were not disclosed.

About Agilent Technologies and Dako

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences,
diagnostics and applied chemical markets, is the premier laboratory partner
for a better world. Agilent works with customers in more than 100 countries,
providing instruments, software, services and consumables for the entire
laboratory workflow. Agilent generated revenues of $4.0 billion in fiscal
2014. The company employs about 12,000 people worldwide. In 2012, Agilent
acquired Dako, a well-known provider of reagents, instruments, software and
expertise to make accurate diagnoses and determine the most effective
treatment for cancer patients. Information about Agilent is available
atwww.agilent.comand information about Dako is available

Editorial Contacts

Agilent Media and Press
Victoria Wadsworth-Hansen
Phone: +45 29336980


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Dako Denmark A/S via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.